Advances of the clinical application of cariprazine, a novel atypical antipsychotic drug
10.13699/j.cnki.1001-6821.2017.16.025
- VernacularTitle:新型非典型抗精神病药——卡利拉嗪的临床应用进展
- Author:
Xiao-Di DONG
1
;
Jin-Guo ZHAI
;
Jing-Ping ZHAO
Author Information
1. 济宁医学院精神卫生学院
- Keywords:
cariprazine;
schizophrenia;
bipolar disorder;
atypical antipsychotic drug;
tolerance
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(16):1601-1603
- CountryChina
- Language:Chinese
-
Abstract:
Cariprazine,a potent dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors,is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar Ⅰ disorder in September 2015.A large number of clinical researches have confirmed that cariprazine has good efficacy,safety and tolerability in the treatment of schizophrenia or bipolar Ⅰ disorder in adults.The aim of this article is to provide an up-to-date review about the mechanism of action,pharmacokinetics,drug-drug interaction,clinical application,safety and tolerance of cariprazine.
